Lerapolturev in Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

February 3, 2023

Conditions
Malignant Glioma
Interventions
BIOLOGICAL

lerapolturev

A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant

DRUG

Lomustine

one cycle of oral lomustine

Trial Locations (6)

27710

Preston Robert Tisch Brain Tumor Center at Duke University, Durham

32207

Baptist MD Anderson Cancer Center, Jacksonville

44106

University Hospitals Cleveland Medical Center, Cleveland

94941

UCSF Neurological Surgery, San Francisco

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

lead

Istari Oncology, Inc.

INDUSTRY